- Home
- MIST vs ALLK Comparison
MIST vs ALLK Comparison
Compare MIST & ALLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- ALLK
- Stock Information
- Founded
- MIST 2003
- ALLK 2012
- Country
- MIST Canada
- ALLK United States
- Employees
- MIST N/A
- ALLK N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- ALLK Biotechnology: Pharmaceutical Preparations
- Sector
- MIST Health Care
- ALLK Health Care
- Exchange
- MIST Nasdaq
- ALLK Nasdaq
- Market Cap
- MIST 100.3M
- ALLK 101.0M
- IPO Year
- MIST N/A
- ALLK 2018
- Fundamental
- Price
- MIST $1.81
- ALLK $1.12
- Analyst Decision
- MIST Strong Buy
- ALLK Hold
- Analyst Count
- MIST 3
- ALLK 5
- Target Price
- MIST $13.00
- ALLK $1.67
- AVG Volume (30 Days)
- MIST 372.6K
- ALLK 306.2K
- Earning Date
- MIST 11-12-2024
- ALLK 11-06-2024
- Dividend Yield
- MIST N/A
- ALLK N/A
- EPS Growth
- MIST N/A
- ALLK N/A
- EPS
- MIST N/A
- ALLK N/A
- Revenue
- MIST N/A
- ALLK N/A
- Revenue This Year
- MIST N/A
- ALLK N/A
- Revenue Next Year
- MIST N/A
- ALLK N/A
- P/E Ratio
- MIST N/A
- ALLK N/A
- Revenue Growth
- MIST N/A
- ALLK N/A
- 52 Week Low
- MIST $1.12
- ALLK $0.54
- 52 Week High
- MIST $2.93
- ALLK $3.36
- Technical
- Relative Strength Index (RSI)
- MIST 49.60
- ALLK 52.99
- Support Level
- MIST $1.76
- ALLK $1.00
- Resistance Level
- MIST $1.86
- ALLK $1.11
- Average True Range (ATR)
- MIST 0.10
- ALLK 0.08
- MACD
- MIST -0.02
- ALLK 0.00
- Stochastic Oscillator
- MIST 18.93
- ALLK 47.73
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About ALLK Allakos Inc.
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.